semaglutide cardiovascular trial news 2.4 mg delivered a statistically significant 20% risk reduction in major adverse events – REGENHEALTHSOLUTIONS (RHS) Semaglutide cardiovascular outcomes align more

Unlike traditional insulin therapy, which directly supplements insulin levels, GLP-1 receptor agonists like semaglutide enhance the bodys natural secretion of insulin in response to increased blood glucose levels

In terms of the primary outcome of reduction in A1C from baseline, although the 3-mg oral semaglutide group did not demonstrate superiority to sitagliptin 100 mg at 26 weeks, the 7-mg and 14-mg dosage groups did demonstrate statistically significant reductions in A1C from baseline when compared with sitagliptin

Show notes Procedural Management of Obesity with Dr

Visaria J, Dang-Tan T, Petraro PV, Nepal BK, Willey V

Metformin is an oral diabetes medication that reduces glucose production in the liver and improves how your cells respond to insulin

Keep protein on your plate